Turning Point Therapeutics, Inc.
TPTXDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oral repotrectinib (TPX-0005) | Phase 2 | Locally Advanced Solid Tumors | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Turning Point Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Turning Point Therapeutics, Inc.'s (TPTX) pipeline across Phase 2. Its lead program is Oral repotrectinib (TPX-0005) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Turning Point Therapeutics, Inc.'s next FDA catalyst?→
Turning Point Therapeutics, Inc.'s (TPTX) next tracked catalyst is a Phase 2 expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TPTX biotech catalysts?→
Add TPTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Turning Point Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.